Ponatinib-d8

Modify Date: 2024-01-09 09:13:51

Ponatinib-d8 structure	Common Name	Ponatinib-d8
	CAS Number	1562993-37-6	Molecular Weight	540.60900
	Density	N/A	Boiling Point	N/A
	Molecular Formula	C₂₉H₁₉D₈F₃N₆O	Melting Point	N/A
	MSDS	N/A	Flash Point	N/A

Use of Ponatinib-d8

Ponatinib D8 (AP24534 D8) is a deuterium labeled Ponatinib. Ponatinib (AP24534) is an orally active multi-targeted kinase inhibitor with IC50s of 0.37 nM, 1.1 nM, 1.5 nM, 2.2 nM, and 5.4 nM for Abl, PDGFRα, VEGFR2, FGFR1, and Src, respectively.

Name	Ponatinib D8
Synonym	More Synonyms

Description	Ponatinib D8 (AP24534 D8) is a deuterium labeled Ponatinib. Ponatinib (AP24534) is an orally active multi-targeted kinase inhibitor with IC50s of 0.37 nM, 1.1 nM, 1.5 nM, 2.2 nM, and 5.4 nM for Abl, PDGFRα, VEGFR2, FGFR1, and Src, respectively.
Related Catalog	Research Areas >> Cancer Signaling Pathways >> Protein Tyrosine Kinase/RTK >> PDGFR Signaling Pathways >> Protein Tyrosine Kinase/RTK >> Src Signaling Pathways >> Protein Tyrosine Kinase/RTK >> Bcr-Abl Signaling Pathways >> Protein Tyrosine Kinase/RTK >> FGFR Signaling Pathways >> Autophagy >> Autophagy Signaling Pathways >> Protein Tyrosine Kinase/RTK >> VEGFR
Target	c-Kit:12.5 nM (IC50) VEGFR2:1.5 nM (IC50) FGFR1:2.2 nM (IC50) PDGFRα:1.1 nM (IC50)
References	[1]. O'Hare T, et al. AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance. Cancer Cell, 2009, 16(5), 401-412.

Molecular Formula	C₂₉H₁₉D₈F₃N₆O
Molecular Weight	540.60900
Exact Mass	540.27000
PSA	65.77000
LogP	4.40480

3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-N-(4-((2,2,3,3,5,5,6,6-octadeutero-4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)benzamide

Ponatinib-d8

Use of Ponatinib-d8

Names

Ponatinib-d8 Biological Activity

Chemical & Physical Properties

Synonyms